Bentysrepinine
Product Specifications
UNSPSC Description
Bentysrepinine (Y101) is an orally active HBV inhibitor with anti-hepatitis B virus infection activity. Bentysrepinine exhibits favorable pharmacokinetic characteristics, with absolute bioavailability of 44.9%, 43.1%, and 19.2% in rats, dogs, and monkeys, respectively, and it does not accumulate in monkeys after 90 days of oral administration. Bentysrepinine is under research in the antiviral and hepatitis fields[1][2].
Target Antigen
HBV
Type
Reference compound
Related Pathways
Anti-infection
Field of Research
Infection; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/bentysrepinine.html
Smiles
CN(C)CCOC(C=C1)=CC=C1C[C@H](NC(C2=CC=CC=C2)=O)C(N[C@H](CO)CC3=CC=CC=C3)=O
Molecular Weight
489.61
References & Citations
[1]Fan H, et al. Metabolite identification of bentysrepinine (Y101), a novel anti-HBV agent in rats using a five-step strategy based on a combined workflow with two different platforms of liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Jan 1;1040:118-128.|[2]Fan H, et al. In vitro metabolism and in vivo pharmacokinetics of bentysrepinine (Y101), an investigational new drug for anti-HBV-infected hepatitis: focus on interspecies comparison. Xenobiotica. 2020 Apr;50(4):468-478.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-111073/Bentysrepinine-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-111073/
Clinical Information
No Development Reported
CAS Number
934264-38-7
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items